

A tailored mobile health intervention to improve adherence and asthma control in minority adolescents

Giselle Mosnaim, MD, MS^a, Hong Li, PhD^a,
Molly Martin, MD, MAPP^b, DeJuran Richardson, PhD^{a,c},
Paula Jo Belice, MS^a, Elizabeth Avery, MSPH^a,
Agustina Silberstein, MD^a, Jason Leigh, PhD^d,
Robert Kenyon, PhD^e, Steve Jones, PhD^f,
Bruce Bender, PhD^g, and Lynda H. Powell, PhD^a

Clinical Implications

- A tailored intervention delivered on a mobile phone platform, integrating low-literacy design strategies and basic principles of behavior change, may be a powerful way to promote increased adherence and asthma control among underserved minority adolescents.

TO THE EDITOR:

Low-income and minority children suffer disproportionately high rates of asthma morbidity.¹ An important contributing factor may be higher rates of low health literacy in underserved populations,² which is associated with poor adherence³ and health outcomes.²

To date, no tailored health literacy intervention has demonstrated objective improvement in adherence to inhaled corticosteroids (ICS) and asthma control in underserved African American adolescents. This treatment group only proof-of-concept study aimed to assess the feasibility and explore the efficacy of an intervention featuring an electronic medication monitor and companion smartphone asthma application to deliver a tailored intervention to improve ICS adherence and asthma control in this low health literacy population. This intervention integrates principles of behavior change based on social cognitive theory⁴ with recommended design strategies for effective communication with low-literacy populations.⁵ Feasibility was measured in terms of acceptability (and use). Efficacy was measured in terms of ability to achieve participant ICS adherence to the clinically significant target ($\geq 50\%$)⁶ and 3-point improvement (minimal clinically important difference = 3) on the Asthma Control Test (ACT).⁷

Study participants met the following inclusion criteria: age 11 to 16 years, African American, a diagnosis of persistent asthma,⁸ possession of an active prescription for ICS verified by pharmacy records, and completion of the baseline run-in protocol. Participants were recruited from the Rush Pediatric Primary Care Center, which serves a primarily urban minority patient population.

The Rush University Medical Center Institutional Review Board approved the study protocol. After each caregiver and child dyad provided written consent and assent, 12 participants entered a 3-week run-in period to determine baseline characteristics and ICS adherence. Adherence was measured using the

Mobile Adolescents' Disease Empowerment and Persistency Technology (M-ADEPT) electronic medication monitor (see Figure E1 in this article's Online Repository at www.jaci-inpractice.org), which was fitted to participants' ICS. All caregivers and adolescents were informed that this device would collect the date and time of each actuation of medication. Upon completion of the run-in period, the 12 adolescents entered the 8-week treatment phase.

For the duration of their participation in this research, all participants received a smartphone (HTC One V, Virgin Mobile USA, Warren, NJ) with an unlimited texting, talking, and data plan (Virgin Mobile USA); ICS (fluticasone propionate HFA MDI 110 μg inhalation aerosol) and short-acting beta₂-agonist (SABA) (albuterol sulfate HFA MDI 90 μg inhalation aerosol) medications (provided by GlaxoSmithKline, Research Triangle Park, NC) fitted with M-ADEPT electronic medication monitors; and the M-ADEPT asthma application loaded onto their study smartphones.

Figure E2 in this article's Online Repository at www.jaci-inpractice.org illustrates the M-ADEPT system. The electronic medication monitors and the smartphone application were developed and built by the investigators (Invention: NIH EIR #0577703-13-0020). The application (Figure 1) was programmed to deliver stimulus control using twice daily visual reminders to take their ICS (Figure 1, A), immediate reinforcement for taking ICS provided by the opportunity to shoot a basket (Figure 1, B) and a positive text message for each ICS puff taken (Figure 1, C), and immediate and long-term rewards each time they completed a full dose of ICS within the pre-selected morning and evening time windows. These rewards included immediate rewards of accessories to customize their game avatar (eg, hairstyles, sunglasses, and animation) as illustrated in Figure 1, D, and the long-term reward of monetary incentives (up to \$1.00/dose) to purchase age-appropriate (ie, radio-edited) music, movies, applications and games for download onto their study smartphones (Figure 1, E).^{4,5} Participants met weekly with an asthma specialist (G.M.) for 30 minutes. The doctor provided standard asthma education as outlined in the asthma guidelines⁸ and tailored feedback (based on participant ICS and SABA use) to promote adherence to ICS. To ensure treatment fidelity, participants met with a research assistant each week to complete questionnaires and testing for proper functioning of their M-ADEPT medication monitoring devices, smartphone, and application.

The primary efficacy outcome was percent daily ICS adherence measured using the electronic medication monitor and truncated at 100% of the prescribed dose. Average daily adherence over the previous 7 days was assessed at baseline and each week of the 8-week treatment phase.

Baseline assessments included demographic characteristics and asthma history. Asthma control (using the ACT)⁹ was assessed at baseline and week 8. Daily SABA use data were collected for the duration of their participation in this research.

Descriptive statistics were used to summarize continuous and discrete variables. Discrete variables were summarized as the total number and percentage in each category. Continuous variables were summarized as the 25th percentile, median, and 75th percentile.




FIGURE 1. The M-ADEPT application. **A-E**, The behavioral principle integrated into each screenshot of the M-ADEPT smartphone application. (A) ICS reminder: stimulus control. (B) Basketball game: immediate reinforcement. (C) Text messages: immediate reinforcement. (D) Avatar rewards: immediate reinforcement. (E) Smartphone rewards: long-term reinforcement.

Of the 12 participants enrolled, 10 completed the 8-week treatment phase, all study data collection instruments, and 80% or more of study visits. For the 2 participants who did not complete the final assessment, the last observation carried forward was used for analyses.

Baseline characteristics of the 12 Medicaid-insured participants who entered the treatment phase include the following: median age of 14 years, 58% girls, 33% reading at 2 or more levels below their grade (measured using the Wide Range Achievement Test-4),¹⁰ and 75% with uncontrolled asthma (ACT score ≤ 19).⁹ Median baseline and week 8 ICS adherence values were 19% and 50% (intent-to-treat)/67% (observed), respectively (Figure 2). Eight percent and 58% of the participants met target ICS adherence ($\geq 50\%$) at baseline and week 8. ACT scores increased from a median of 18 at baseline to 23 at

week 8. Fifty-eight percent of the participants achieved the minimal clinically important difference (3 points) in ACT score from baseline to week 8.⁷ SABA use decreased from a median of 3 puffs per week at baseline to 0 puffs per week at 8 weeks.

Cognizant of important limitations (short time frame, small sample size, inclusion of participants from only 1 racial/ethnic group, and lack of a control group), this M-ADEPT–tailored low health literacy intervention is the first to demonstrate objective improvement in ICS adherence⁵ and asthma control⁷ among underserved minority adolescents. Eighty-three percent of the adolescents completed the 8-week treatment, indicating that the intervention was acceptable and feasible in our target population.

M-ADEPT integrates design strategies for communication with low-literacy populations⁵ and principles of behavior change⁶




FIGURE 2. Median percent ICS adherence at baseline and during treatment. This represents median ICS adherence at baseline and each week of the 8-week active treatment phase for the cohort of study participants.

delivered on a mobile phone to improve health outcomes. The quasi-experimental, treatment-only design of this study is consistent with recommendations for early preliminary testing of a new intervention.¹¹ These promising results merit further testing of this intervention in a larger and more diverse sample using a rigorous randomized design. Studies are needed to test whether a longer duration of M-ADEPT intervention (12 months) may lead to long-lasting (ie, 2-5 years) maintenance of clinically significant ICS adherence. It is hypothesized that a 12-month improvement in ICS adherence will translate to decreased impairment and risk over a sufficiently long period of time for adolescents to make the connection between medication-taking behavior and asthma control. This, in turn, will intrinsically motivate them to continue their adherent behavior to maintain asthma control without reliance on the M-ADEPT intervention. Future studies should seek to understand the M-ADEPT hypothesized pathways for efficacy and impact on clinical asthma outcomes such as emergency department visits and hospitalizations, and include a cost-effectiveness analysis.

Acknowledgments

We thank Brent Grossman, MS, Steve Conner, MS, and Joshua Albers, MFA, for their assistance with technology development.

^aDepartment of Preventive Medicine, Rush Medical College, Chicago, Ill

^bDepartment of Pediatrics, University of Illinois at Chicago, Chicago, Ill

^cDepartment of Mathematics and Computer Studies, Lake Forest College, Lake Forest, Ill

^dInformation and Computer Sciences Department, University of Hawaii at Manoa, Manoa, Hawaii

^eDepartment of Computer Science, University of Illinois at Chicago, Chicago, Ill

^fDepartment of Communications, University of Illinois at Chicago, Chicago, Ill

^gDepartment of Pediatrics, National Jewish Health, Denver, Colo

This study was supported by the National Heart, Lung, and Blood Institute (grant no. K23 HL092292 and grant no. R21 HL098812) and the University of Illinois at Chicago Center for Clinical and Translational Science (grant no. UL1RR02789) and is part of the Rush Center for Urban Health Equity, which is funded by the National Heart, Lung, and Blood Institute (grant no. 1P50HL105189). Support in the form of the study drug was provided by GlaxoSmithKline (grant no. FLV117251).

Conflicts of interest: B. Bender has received consultancy and lecture fees from Merck and has received research support from GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication June 30, 2014; revised October 16, 2014; accepted for publication October 17, 2014.

Available online January 13, 2015.

Corresponding author: Giselle Mosnaim, MD, MS, Department of Preventive Medicine, Rush University Medical Center, 1700 West Van Buren, Ste 470, Chicago, IL 60612. E-mail: giselle_mosnaim@rush.edu.

2213-2198

© 2015 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaip.2014.10.011>

REFERENCES

- Moorman JE, Zahran H, Truman B, Molla M, Centers for Disease Control and Prevention (CDC). Current asthma prevalence—United States, 2006-2008. *MMWR Surveill Summ* 2011;60:84-6.
- Berkman ND, De Walt DA, Pignone MP, Sheridan SL, Lohr KN, Lux L, et al. Literacy and health outcomes. *Evid Rep Technol Assess (Summ)* 2004;87:1-8.
- Gazmararian JA, Kriplani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. *J Gen Intern Med* 2006;21:1215-21.
- Bandura A. *Social Foundations of Thought and Action: A Social Cognitive Theory*. Englewood Cliffs, NJ: Prentice-Hall; 1986. p 523-82.
- Doak C, Doak L, Root J. *Teaching Patients With Low Literacy Skills*. 2nd ed. Philadelphia, Pa: J. B. Lippincott Company; 1996.
- Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. *N Engl J Med* 2000;343:332-6.
- Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. *J Allergy Clin Immunol* 2009;124:719-23.e1.
- National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health; Full Report 2007. p 1-440.
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;113:59-65.
- Wilkinson GS, Robertson GJ. *Wide Range Achievement Test 4: Professional Manual*. Lutz, Fla: Psychological Assessment Resources; 2006.
- Czajkowski SM, Powell LH, Adler N, Naar-King S, Reynolds KD, Hunter CM, et al. From ideas to efficacy: the ORBIT model for developing behavioral treatments for chronic diseases. *Health Psychol*. In press.



FIGURE E1. The M-ADEPT electronic medication monitor. This figure illustrates the hardware and case of the M-ADEPT electronic medication monitor. The hardware is composed of a microcontroller and a bluetooth modem. An open-source 3D modeling tool, Blender (blender.org), was used to design the cases housing the electronic components and the medication (constructed using a fused filament fabrication 3D printer). 3D, 3-Dimensional.




FIGURE E2. The M-ADEPT system. The flow of information between the M-ADEPT electronic medication monitors, smartphone application, Health Cloud, asthma clinician, and study participant.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.